CAR-T cell therapy for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18 or older) with a confirmed diagnosis of multiple myeloma
- You have enough myeloma in your body to measure it (for example, specific blood or urine protein levels, or a biopsy-proven plasmacytoma)
- You’ve had at least 3 prior treatment regimens for multiple myeloma
- A recent bone marrow test (within 30 days) shows at least 10% plasma cells in the bone marrow
- You must be able to give apheresis materials (leukapheresis) and meet key safety labs: neutrophils ≥500, platelets ≥30,000, hemoglobin >8
- You likely must have had no major anti-myeloma treatment or high-dose steroids within set time windows, and your heart pumping function must be adequate (ejection fraction ≥45%)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
This Phase 1 study tests an experimental CAR T-cell treatment that targets BCMA in people with relapsed or refractory multiple myeloma. It may help shrink the cancer after it has not responded to several prior therapies.
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
This trial tests a new type of cell therapy (CAR-T cells) that is designed to find and destroy myeloma cells that have a protein called BCMA. It is for people whose multiple myeloma has come back or hasn't responded to other treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.